Antihypertensive therapy, the α-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: The genetics of hypertension-associated treatment study

Pharmacogenomics Journal

Volumn 7, Issue 2, 2007, Pages 112-122

  Davis, B R ^a   Arnett, D K ^b   Boerwinkle, E ^a   Ford, C E ^a   Leiendecker Foster, C ^c   Miller, M B ^d   Black, H ^e   Eckfeldt, J H ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADDUCIN; AMLODIPINE; CHLORTALIDONE; DOXAZOSIN; ESTROGEN; GLYCINE; LISINOPRIL; TRYPTOPHAN;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALMODULIN-BINDING PROTEINS; CHLORTHALIDONE; CORONARY DISEASE; DOUBLE-BLIND METHOD; DOXAZOSIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCINE; HUMANS; HYPERTENSION; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LISINOPRIL; MALE; MIDDLE AGED; PATIENT SELECTION; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 34147126026     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500395     Document Type: Article

References (45)

1. Glover MJ, Greenlund KT, Ayala C, Croft JB. Racial/ethnic disparities in prevalence, treatment, and control of hypertension - United States, 1999-2002. MMWR 2005; 54: 7-9.
2. Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4: 151-160.
3. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H et al. Angiotensinogen gene polymorphisms: Relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17: 8-13.
4. Katsuya T, Iwashima Y, Sugimoto K, Motone M, Asai T, Fukuda M et al. Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 2001; 24: 463-467.
5. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41: 398-403.
6. Cadman PE, O'Connor DT. Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens 2003; 12: 61-70.
7. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-1357.
8. Castellano M, Barlassina C, Muiesan ML, Beschi M, Cinelli A, Rossi F et al. Alpha-adducing gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 1997; 15: 1707-1710.
9. Kato N, Sugiyama T, Nabika T, Morita H, Kurihara H, Yazaki Y et al. Lack of association between the alpha-adducin locus and essential hypertension in the Japanese population. Hypertension 1998; 31 730-733.
10. Wang WY, Adams DJ, Glenn CL, Morris BJ. The Gly460Trp variant of alpha-adducin is not associated with hypertension in white Anglo-Australians. Am J Hypertens 1999; 12: 632-636.
11. Schork NJ, Chakravarti A, Thiel B, Fornage M, Jacob HJ, Cai R et al. Lack of association between a biallelic polymorphism in the adducin gene and blood pressure in whites and African Americans. Am J Hypertens 2000; 13: 693-698.
12. Province MA, Arnett DK, Hunt SC, Leiendecker-Foster C, Eckfeldt JH, Oberman A et al. Association between the alpha-adducin gene and hypertension in the HyperGEN Study. Am J Hypertens 2000; 13: 710-718.
13. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright Jr JT, Cushman WC et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9: 342-360.
14. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2002; 2: 309-317.
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975.
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
17. Special Emphasis Panel. Report of the special emphasis panel on opportunities and obstacles to genetic research in NHLBI clinical studies. In: National Heart, Lung, and Blood Institute, National Institutes of Health 1997.
18. Morrison AC, Bray MS, Folsom AR, Boerwinkle E. ADD1 460W allele associated with cardiovascular disease in hypertensive individuals. Hypertension 2002; 39: 1053-1057.
19. Nicod J, Frey BM, Frey FJ, Ferrari P. Role of the alpha-adducin genotype on renal disease progression. Kidney Int 2002; 61: 1270-1275.
20. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004; 15: 535-541.
21. Tahmatzopoulos A, Rowland RG, Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother 2004; 5: 1279-1285.
22. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287: 1680-1689.
23. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16: 834-839.
24. Schelleman H, Stricker BH, Verschuren WM, de Boer A, Kroon AA, de Leeuw PW et al. Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J 2006; 6: 22-26.
25. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34: 649-654.
26. Naber CK, Siffert W. Genetics of human arterial hypertension. Minerva Med 2004; 95: 347-356.
27. Bianchi G, Tripodi MG, Casari G, Salardi S, Barber BR, Garcia R et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 1994; 91: 3999-4003.
28. Wang JG, Staessen JA, Barlassina C, Fagard R, Kuznetsova T, Stuijker-Boudier HA et al. Association between hypertension and variation in the alpha- and beta-adducin genes in a white population. Kidney Int 2002; 62: 2152-2159.
29. Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhager WH, Herrmann SM et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens 2001; 19: 1349-1358.
30. Grant FD, Romero JR, Jeunemaitre X, Hunt SC, Hopkins PN, Hollenberg NH et al. Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism. Hypertension 2002; 39: 191-196.
31. Glorioso N, Filigheddu F, Cusi D, Troffa C, Conti M, Natalizio M et al. Alpha-adducin 460Trp allele is associated with erythrocyte Na transport in North Sardinian primary hypertensives. Hypertension 2002; 39: 357-362.
32. Wang JG, Liu L, Zagato L, Xie J, Fagard R, Jin K et al. Blood pressure in relation to three candidate genes in a Chinese population. J Hypertens 2004; 22: 937-944.
33. Ferrandi M, Salardi S, Tripodi MG, Barassi P, Rivera R, Manunta P et al. Evidence for an interaction between adducin and Na-K-ATPase: relation to genetic hypertension. Am J Physiol 1999; 277: H1338-H1349.
34. Tripodi MG, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino L et al. Hypertension associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 1996; 97: 2815-2822.
35. Bianchi G, Ferrari P, Staessen JA. Adducin polymorphism detection and impact on hypertension. Hypertension 2005; 45: 331-340.
36. Manunta P, Cusi D, Barlassina C, Righetti M, Lanzani C, D'Amico M et al. Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int 1998; 53: 1471-1478.
37. Manunta P, Burnier M, D'Amico M, Buzzi L, Maillard M, Barlassina C et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33: 694-697.
38. Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential hypertension. Lancet 2003; 361: 1629-1641.
39. Yamagishi K, Iso H, Tanigawa T, Cui R, Kudo M, Shimamoto T. Alpha-adducin G460W polymorphism, urinary sodium excretion, and blood pressure in community-based samples. Am J Hypertens 2004; 17 385-390.
40. Wang JG, Staessen JA, Barlassina C, Fagard R, Kuznetsova T, Struijker-Boudier HA et al. Association between hypertension and variation in the α- and β-adducin genes in a white population. Kidney Int 2002; 62: 2152-2159.
41. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62: 1718-1723.
42. Bachman J, Feldmer M, Ganten U et al. Sexual dimorphism of blood pressure: Possible role of the rennin-angiotensin system. J Steroid Biochem Mol Biol 1991; 40: 511-515.
43. Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H. Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses - a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study. Stat Med 2004; 23: 2413-2427.
44. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
45. Kostis JB, Davis BR, Cutler J, Grimm Jr RH, Berge KG, Cohen JD et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278: 212-216.